PEG-MGF

No published study in the sources behind PEG-MGF gave it to a person. The human data attached to the name is a single biopsy study in 15 healthy men that measured the body's own MGF splice variant, a messenger RNA, after one heavy leg session. It rose in the 8 young men and not in the 7 elderly men.

The rest is cell culture and animal work on unpegylated synthetic MGF, alongside a 2010 review in Endocrinology that found no evidence a peptide matching synthetic MGF is made in living tissue at all. FDA lists the pegylated form apart from its parent, and its published concern is that no human exposure data has been identified for any route of administration. Mechano growth factors are prohibited at all times under WADA S2.3.

The IGF-1 gene is spliced into several transcripts. One of them, called IGF-IEb in rodents and IGF-IEc in humans, rises in loaded or damaged muscle, and the London group that cloned it from stretched, electrically stimulated rabbit muscle named it mechano growth factor.

The same three letters were later given to a synthetic peptide: the final 24 amino acids that the transcript would encode. Matheny and colleagues note that MGF has been used for the mRNA, for a precursor protein and for the laboratory peptide, and propose keeping the term for the synthetic peptide only. PEG-MGF is that synthetic peptide with a polyethylene glycol chain attached. None of the studies reviewed here used the pegylated version.

What the Synthetic Peptide Does in Culture

Yang and Goldspink tested the MGF E domain on C2C12 mouse myoblasts in 2002. Unlike mature IGF-1, it raised proliferation and inhibited terminal differentiation, and blocking the IGF-1 receptor with an antibody pointed to a different receptor doing the work. Later cell studies summarized by Matheny found synthetic MGF switched on ERK but not Akt in C2C12 myoblasts and H9c2 heart cells.

From those results came what Matheny calls the MGF hypothesis: an early MGF signal expands muscle precursor cells after loading or injury, and mature IGF-1 then drives differentiation and growth. It is a tidy two-stage model, and it explains why the compound attracts interest.

The Step Nobody Has Shown

For the culture data to describe something the body does, a 24 amino acid peptide has to be cut from the IGF-1 precursor inside living tissue. Matheny's review reports that no such peptide has been identified in or isolated from cultured cells, their conditioned medium, animal tissues or biological fluids, and that the required processing step has not been observed in any system to date. Its verdict is that the evidence for MGF being a product of Igf1 gene expression in vivo is inadequate.

So the mechanism describes a synthetic molecule acting on cells. Whether it mirrors any signal released during training is unresolved, and pegylation is a further change that no study here examined.

The usual pitch runs: training raises MGF, age blunts that rise, so PEG-MGF puts it back. Every link in that chain has a gap.

A transcript is treated as a peptide. The human finding is about mRNA in a biopsy. Matheny's review found no evidence that the matching 24 amino acid peptide is produced in living tissue, so more transcript is not evidence of more peptide.

One small study is treated as a rule. The age difference rests on 15 men sampled at one time point, and a later study in young men using similar methods did not see the rise.

A culture dish is treated as a muscle. Faster division of mouse myoblasts is not muscle growth or quicker recovery in a person, and no human trial has tested either outcome.

MGF is treated as PEG-MGF. Every experimental source used unpegylated material or the body's own transcript. Findings on the parent are being lent to a different molecule, one FDA itself lists as a separate substance.

There are no human safety data for PEG-MGF or for unpegylated synthetic MGF in these sources, because no study gave either one to a person. FDA's stated concern about the pegylated form is that no human exposure data has been identified for any route of administration.

What is actually sold is a measured problem. Both black-market preparations analysed by Esposito and colleagues were an amidated analogue rather than human MGF. The product examined by Thevis and colleagues was a modified full-length protein of about 12.3 kDa, not the 24 amino acid peptide, and it proved detectable at 0.25 ng/mL using adapted routine doping-control methods.

WADA lists mechano growth factors under S2.3, growth factors and growth factor modulators. The pegylated form is not printed by name; the class wording is what covers it. The class is prohibited at all times, in and out of competition, as a non-specified substance.

The human statement that holds up is narrow. In one study of 15 healthy men, a heavy leg session raised the body's own MGF transcript in the young men and not in the old, and a later study did not repeat the rise in young men. That is a finding about loading and gene expression.

It does not reach PEG-MGF. Getting from that biopsy result to a vial needs an endogenous peptide nobody has isolated, cell effects never tested in people, and a pegylated molecule that none of the studies examined. Of all those pieces, only the training itself has been looked at in humans.

Not a peptide shown to exist in the body. Matheny and colleagues (Endocrinology, 2010) report that no matching peptide has been identified in cells, conditioned medium, animal tissues or biological fluids.

Not the molecule the human study measured. The 2002 biopsy study measured the men's own MGF messenger RNA in muscle; it neither measured a peptide nor gave one.

Not covered by its parent's FDA status. FDA lists “Mechano growth factor pegylated (PEG-MGF)” separately from “Mechano growth factor (MGF)”. The parent sits in Category 3, meaning it was nominated with insufficient supporting information to evaluate, and that placement is not a status for the pegylated form. PEG-MGF is on neither the Category 1 nor the Category 2 list: it left Category 2 on or about 2026-04-22 because the nominators withdrew the nomination, not because FDA resolved its safety concerns, and those concerns remain published.

Not yet ruled on by FDA's advisory committee. FDA has announced it intends to consult the advisory committee on PEG-MGF before the end of February 2027. A planned consultation is not a decision.

Not permitted in tested sport. WADA S2.3 names “Mechano growth factors (MGFs)”, and that class wording captures the pegylated form, prohibited at all times.

I keep PEG-MGF in the library because the biology underneath it is real and worth knowing. Muscle changes how it splices the IGF-1 gene when it is loaded, and one small study suggests older muscle does it less readily, though a later study muddied even the young-muscle result. That is a reason to understand training, and it is the whole of what the human data shows.

What I will not do is let that finding stand in for the product. No study I reviewed gave PEG-MGF to anyone, the peptide it is built on has not been shown to exist in living tissue, and the material sold under the MGF name has twice been analysed and found to be something else. I am not going to describe a pegylated synthetic peptide with no human exposure data as a recovery tool.